Study identifier:D6992C00044
ClinicalTrials.gov identifier:NCT00278915
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (fulvestrant) in Girls with Progressive Precocious Puberty Associated with McCune-Albright Syndrome
Puberty, Precocious, McCune-Albright Syndrome
Phase 2
No
Fulvestrant
Female
30
Interventional
1 Years - 10 Years
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2022 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: Fulvestrant intramuscular injection Other Name: Faslodex Other Name: ZD9238 |